Inovio: FDA Approval of the First DNA Medicine Turns a 75% Loser Into the Only Commercial Plasmid Platform on Earth

Inovio spent three decades building a plasmid DNA-medicine platform: engineered DNA constructs delivered into cells by CELLECTRA, its proprietary electroporation device, which uses brief electrical pulses to open cell membranes. The commercial model is now classic rare-disease biotech — Voceryq treats adult recurrent respiratory papillomatosis, an orphan indication with no approved drug alternative and a surgical standard of care, so pricing power comes from Breakthrough and Orphan Drug designations rather than volume.

Launch is outsourced and asset-light: Syneos Health recruits medical science liaisons and runs the contract sales organization, while a specialty distributor, specialty pharmacy and patient hub handle fulfillment and access. That keeps 2026 burn near $18 million per quarter but means gross-to-net economics, payer coverage and label-driven patient identification — all still undisclosed — will determine 2027 revenue.

Beyond Voceryq, the platform monetizes three ways: partnered programs (ApolloBio's successful VGX-3100 Phase 3 in cervical dysplasia heads toward Chinese approval), out-licensing of next-gen DNA-encoded protein candidates in hemophilia A, Fabry and hypophosphatasia, and the CELLECTRA device itself as the delivery standard for any future in-house or partnered DNA medicine. Each path carries milestone and royalty economics rather than heavy internal spend, which matters for a company guiding to roughly $18 million of quarterly burn and a balance sheet with only $4.4 million of book equity behind 103.4 million shares.

Full-Year Trajectory (TTM)

Quarterly Progression

Balance Sheet Snapshot

Guidance: no revenue guidance. Management estimates ≈$18M Q3 2026 cash burn and runway into late Q1 2027 with no further raises assumed; Voceryq orderable and shipping in ≈60 days with full field deployment in Q1 2027; confirmatory-study draft protocol due to FDA by end of 2026, final protocol alignment expected mid-2027. Q3 2026 results are estimated for November 13, 2026 — the first post-approval financial print.

Voceryq enters a market with no FDA-approved drug competitor: RRP has been managed for decades by surgical debulking plus off-label injections, an approach that never clears the virus from airway tissue and leaves patients cycling through the operating room for life. That vacuum is simultaneously the opportunity, the pricing argument and the validation burden — Inovio must convince laryngologists, who have watched off-label therapies disappoint for thirty years, to try a two-plasmid electroporated immunotherapy in patients who average 4.5 surgeries a year. The FDA's Breakthrough and Orphan designations, published Nature Communications data and an endorsement from the RRP Foundation are the adoption accelerants.

• Merck (MRK): Gardasil vaccinates against HPV 6/11 — prevention at the population level, but no product for established airway papillomatosis; Merck is the franchise owner of the disease's cause, not its treatment.
• Roche/Genentech (RHHBY): Bevacizumab (Avastin) injections are the most-used off-label adjuvant for aggressive RRP; an approved on-label immunotherapy with a surgery-reduction endpoint directly challenges that gray-market standard.
• Gilead (GILD): Cidofovir (Vistide), another off-label intralesional option with nephrotoxicity concerns, rounds out the legacy toolkit Voceryq displaces.
• GeneOne Life Science (KOSDAQ-listed): Fellow DNA-plasmid developer — and Inovio's litigation counterparty; the $80.4M judgment underscores both the platform's supply-chain scars and the scarcity of credible plasmid-medicine rivals.
• Ionis/Arrowhead-type genetic-medicine platforms: RNA and gene-editing competitors pursue adjacent rare-disease budgets, but none has a delivered-DNA product on the U.S. market.

Moats:

1. First-and-only FDA-approved plasmid DNA medicine, with Orphan exclusivity for Voceryq in RRP.
2. CELLECTRA electroporation delivery — a device-drug combination that competitors would need years and their own approvals to replicate.
3. Published clinical backbone (Nature Communications, The Laryngoscope) and RRP Foundation endorsement that shorten specialist adoption curves.

1. Voceryq commercial availability — orderable and shipping in ≈60 days from the October 30 approval, with full field deployment in Q1 2027 and pricing disclosure expected at or before launch.
2. November 13, 2026 (estimated): Q3 2026 results — first post-approval look at cash burn, the ≈$18M quarterly guide, and any launch-spending detail.
3. End of 2026: deadline to submit the draft confirmatory-study protocol to the FDA, with final alignment expected by mid-2027.
4. ApolloBio's China regulatory filing for VGX-3100 following its positive Phase 3, unlocking partner economics.
5. DPROT platform partnerships in hemophilia A, Fabry or hypophosphatasia, plus any update on collection or settlement of the $80.4M VGXI/GeneOne judgment.